Search

Your search keyword '"Carey, Mark S."' showing total 287 results
Start Over Author "Carey, Mark S."
287 results on '"Carey, Mark S."'

1. Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer

Author

Kumar, Pooja Praveen, Smith, DuPreez, Key, James, Dong, He, Ganapathysamy, Ashtalakshmi, Maranda, Vincent, Wong, Nelson K.Y., Fernandez, Marta Llaurado, Kim, Hannah, Zhang, Guihua, Ewanowich, Carol, Hopkins, Laura, Freywald, Andrew, Postovit, Lynne M., Köbel, Martin, Fu, Yangxin, Vizeacoumar, Frederick S., Vizeacoumar, Franco J., Carey, Mark S., and Lee, Cheng-Han

Published
2024
Full Text
View/download PDF

2. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma

Author

Hollis, Robert L., Elliott, Richard, Dawson, John C., Ilenkovan, Narthana, Matthews, Rosie M., Stillie, Lorna J., Oswald, Ailsa J., Kim, Hannah, Llaurado Fernandez, Marta, Churchman, Michael, Porter, Joanna M., Roxburgh, Patricia, Unciti-Broceta, Asier, Gershenson, David M., Herrington, C. Simon, Carey, Mark S., Carragher, Neil O., and Gourley, Charlie

Published
2024
Full Text
View/download PDF

4. Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma

Author

Wong, Nelson K.Y., Llaurado Fernandez, Marta, Kommoss, Felix K.F., Praveen Kumar, Pooja, Kim, Hannah, Liu, Jiahui, Zhang, Guihua, Coatham, Mackenzie, Lin, Yen-Yi, Haegert, Anne M., Volik, Stanislav, Le Bihan, Stephane, Collins, Colin C., Fu, Yangxin, Postovit, Lynne M., von Deimling, Andreas, Wu, Rebecca, Xue, Hui, Wang, Yuzhuo, Köbel, Martin, Carey, Mark S., and Lee, Cheng-Han

Published
2023
Full Text
View/download PDF

6. Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression

Author

Cheasley, Dane, Fernandez, Marta Llaurado, Köbel, Martin, Kim, Hannah, Dawson, Amy, Hoenisch, Joshua, Bittner, Madison, Chiu, Derek S., Talhouk, Aline, Gilks, C. Blake, Jayawardana, Madawa W., Pishas, Kathleen I., Mes-Masson, Anne-Marie, Provencher, Diane, Nigam, Abhimanyu, Hacker, Neville F., Gorringe, Kylie L., Campbell, Ian G., and Carey, Mark S.

Published
2022
Full Text
View/download PDF

7. Ovarian carcinosarcomas: p53 status defines two distinct patterns of oncogenesis and outcomes.

Author

Dhillon, Gurdial, Llaurado-Fernandez, Marta, Tessier-Cloutier, Basile, Sy, Keiyan, Bassiouny, Dina, Guangming Han, Wong, Nelson K. Y., McRae, Kathryn, Kinloch, Mary, Pors, Jennifer, Hopkins, Laura, Covens, Allan, Köbel, Martin, Cheng-Han Lee, and Carey, Mark S.

Subjects
RENAL cell carcinoma, SOMATIC mutation, OVERALL survival, LOG-rank test, PROGRESSION-free survival, OVARIAN cancer
Abstract

Objectives: Ovarian carcinosarcoma (OCS) is a rare and lethal type of ovarian cancer. Despite its incredibly poor prognosis, it has received little research attention. In this study, we aim to evaluate the molecular features of OCS and elucidate their clinical significance. Study methods: We examined 30 OCS by immunohistochemistry (IHC) and targeted panel sequencing collected from a single institution (2003–2013) as the initial molecularly characterized cohort (Cohort A). From November 2016 to April 2023, we collected an additional 67 OCS cases from three institutions across British Columbia and Alberta as the contemporary cohort (Cohort B) for clinical correlation. The Kaplan–Meier method was used to estimate overall and progression-free survival, and differences in survival rates were compared using the log-rank test. All tests were two-sided. A p-value of less than 0.05 was considered statistically significant. Results: The majority of OCS (82%) in the initial Cohort A were p53-mutated, and the carcinomatous component displayed the histological and molecular features of a high-grade tubo-ovarian serous carcinoma (HGSC-like). In a minority of OCS, the epithelial components were characteristics of endometrioid or clear cell carcinomas, and IHC staining was wild type for p53. In the contemporary Cohort B, we observed the same histological findings related to the p53 IHC staining pattern. The median overall survival of the p53-mutated HGSC-like OCS (47 patients) was significantly higher (43.5 months) compared with that of the p53 wild-type OCS (10 patients, 8.8 months; P < 0.01). Pathogenic BRCA1/2 germline/ somatic mutations were observed in 7 patients (17.5%) of HGSC-like OCS, and all these patients were alive at 3 years from diagnosis compared to a 51% 3-year survival among the patients with BRCA1/2 wild-type HGSC-like OCS (33 patients) (p = 0.022). Majority of patients (6/7) with BRCA1/2-mutated OCS received poly (ADP-ribose) polymerase inhibitor as maintenance therapy in this cohort. Conclusions: Most OCSs have a morphologic and molecular profile resembling HGSC; however, some OCSs display a molecular profile that suggests origin through non-serous oncogenic pathways. This molecular distinction has both prognostic and treatment (predictive) implications. These findings underscore the importance of routine p53 IHC testing on all OCS and BRCA1/2 testing on p53-mutated OCS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes

Author

Scott, Stephanie A., Llaurado Fernandez, Marta, Kim, Hannah, Elit, Laurie, Nourmoussavi, Melica, Glaze, Sarah, Roberts, Lesley, Offman, Saul L., Rahimi, Kurosh, Lytwyn, Alice, Sur, Monalisa, Gilks, C. Blake, Matheson, Kara, Köbel, Martin, Dawson, Amy, Tinker, Anna V., Kwon, Janice S., Hoskins, Paul, Santos, Jennifer L., Cheung, Andrea, Provencher, Diane, and Carey, Mark S.

Published
2020
Full Text
View/download PDF

11. Low-grade serous ovarian cancer: State of the science

Author

Slomovitz, Brian, Gourley, Charlie, Carey, Mark S., Malpica, Anais, Shih, Ie-Ming, Huntsman, David, Fader, Amanda N., Grisham, Rachel N., Schlumbrecht, Matthew, Sun, Charlotte C., Ludemann, Jane, Cooney, Gail Austin, Coleman, Robert, Sood, Anil K., Mahdi, Haider, Wong, Kwong K., Covens, Allan, O'Malley, David M., Lecuru, Fabrice, Cobb, Lauren P., Caputo, Thomas A., May, Taymaa, Huang, Marilyn, Siemon, John, Fernández, Marta Llauradó, Ray-Coquard, Isabelle, and Gershenson, David M.

Published
2020
Full Text
View/download PDF

12. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas

Author

Köbel, Martin, primary, Yang, Rui Zhe, additional, Kang, Eun Young, additional, Al-Shamma, Zainab, additional, Cook, Linda S., additional, Kinloch, Mary, additional, Carey, Mark S., additional, Hopkins, Laura, additional, Nelson, Gregg S., additional, McManus, Kirk J., additional, Vizeacoumar, Frederick S., additional, Vizeacoumar, Franco J., additional, Freywald, Andrew, additional, Fu, YangXin, additional, Reuss, David E., additional, and Lee, Cheng-Han, additional

Published
2023
Full Text
View/download PDF

14. Low-grade serous ovarian cancer: expert consensus report on the state of the science

Author

Grisham, Rachel N, primary, Slomovitz, Brian M, additional, Andrews, Nicole, additional, Banerjee, Susana, additional, Brown, Jubilee, additional, Carey, Mark S, additional, Chui, Herman, additional, Coleman, Robert L, additional, Fader, Amanda N, additional, Gaillard, Stephanie, additional, Gourley, Charlie, additional, Sood, Anil K, additional, Monk, Bradley J, additional, Moore, Kathleen N, additional, Ray-Coquard, Isabelle, additional, Shih, Ie-Ming, additional, Westin, Shannon N, additional, Wong, Kwong-Kwok, additional, and Gershenson, David M, additional

Published
2023
Full Text
View/download PDF

16. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer

Author

Gonzalez-Angulo, Ana M, Hennessy, Bryan T, Meric-Bernstam, Funda, Sahin, Aysegul, Liu, Wenbin, Ju, Zhenlin, Carey, Mark S, Myhre, Simen, Speers, Corey, Deng, Lei, Broaddus, Russell, Lluch, Ana, Aparicio, Sam, Brown, Powel, Pusztai, Lajos, Symmans, W Fraser, Alsner, Jan, Overgaard, Jens, Borresen-Dale, Anne-Lise, Hortobagyi, Gabriel N, Coombes, Kevin R, and Mills, Gordon B

Subjects
Cancer, Breast Cancer, Clinical Research, Biochemistry & Molecular Biology
Abstract

PurposeTo determine whether functional proteomics improves breast cancer classification and prognostication and can predict pathological complete response (pCR) in patients receiving neoadjuvant taxane and anthracycline-taxane-based systemic therapy (NST).MethodsReverse phase protein array (RPPA) using 146 antibodies to proteins relevant to breast cancer was applied to three independent tumor sets. Supervised clustering to identify subgroups and prognosis in surgical excision specimens from a training set (n = 712) was validated on a test set (n = 168) in two cohorts of patients with primary breast cancer. A score was constructed using ordinal logistic regression to quantify the probability of recurrence in the training set and tested in the test set. The score was then evaluated on 132 FNA biopsies of patients treated with NST to determine ability to predict pCR.ResultsSix breast cancer subgroups were identified by a 10-protein biomarker panel in the 712 tumor training set. They were associated with different recurrence-free survival (RFS) (log-rank p = 8.8 E-10). The structure and ability of the six subgroups to predict RFS was confirmed in the test set (log-rank p = 0.0013). A prognosis score constructed using the 10 proteins in the training set was associated with RFS in both training and test sets (p = 3.2E-13, for test set). There was a significant association between the prognostic score and likelihood of pCR to NST in the FNA set (p = 0.0021).ConclusionWe developed a 10-protein biomarker panel that classifies breast cancer into prognostic groups that may have potential utility in the management of patients who receive anthracycline-taxane-based NST.

Published
2011

17. Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

Author

Llaurado Fernandez, Marta, primary, Hijmans, E. Marielle, primary, Gennissen, Annemiek M.C., primary, Wong, Nelson K.Y., primary, Li, Shang, primary, Wisman, G. Bea A., primary, Hamilton, Aleksandra, primary, Hoenisch, Joshua, primary, Dawson, Amy, primary, Lee, Cheng-Han, primary, Bittner, Madison, primary, Kim, Hannah, primary, DiMattia, Gabriel E., primary, Lok, Christianne A.R., primary, Lieftink, Cor, primary, Beijersbergen, Roderick L., primary, de Jong, Steven, primary, Carey, Mark S., primary, Bernards, René, primary, and Berns, Katrien, primary

Published
2023
Full Text
View/download PDF

18. Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

Author

Llaurado Fernandez, Marta, primary, Hijmans, E. Marielle, primary, Gennissen, Annemiek M.C., primary, Wong, Nelson K.Y., primary, Li, Shang, primary, Wisman, G. Bea A., primary, Hamilton, Aleksandra, primary, Hoenisch, Joshua, primary, Dawson, Amy, primary, Lee, Cheng-Han, primary, Bittner, Madison, primary, Kim, Hannah, primary, DiMattia, Gabriel E., primary, Lok, Christianne A.R., primary, Lieftink, Cor, primary, Beijersbergen, Roderick L., primary, de Jong, Steven, primary, Carey, Mark S., primary, Bernards, René, primary, and Berns, Katrien, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

Author

Llaurado Fernandez, Marta, primary, Hijmans, E. Marielle, primary, Gennissen, Annemiek M.C., primary, Wong, Nelson K.Y., primary, Li, Shang, primary, Wisman, G. Bea A., primary, Hamilton, Aleksandra, primary, Hoenisch, Joshua, primary, Dawson, Amy, primary, Lee, Cheng-Han, primary, Bittner, Madison, primary, Kim, Hannah, primary, DiMattia, Gabriel E., primary, Lok, Christianne A.R., primary, Lieftink, Cor, primary, Beijersbergen, Roderick L., primary, de Jong, Steven, primary, Carey, Mark S., primary, Bernards, René, primary, and Berns, Katrien, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability

Author

Shrestha, Raunak, primary, Llaurado Fernandez, Marta, primary, Dawson, Amy, primary, Hoenisch, Joshua, primary, Volik, Stanislav, primary, Lin, Yen-Yi, primary, Anderson, Shawn, primary, Kim, Hannah, primary, Haegert, Anne M., primary, Colborne, Shane, primary, Wong, Nelson K.Y., primary, McConeghy, Brian, primary, Bell, Robert H., primary, Brahmbhatt, Sonal, primary, Lee, Cheng-Han, primary, DiMattia, Gabriel E., primary, Le Bihan, Stephane, primary, Morin, Gregg B., primary, Collins, Colin C., primary, and Carey, Mark S., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Data from Pharmacodynamic Markers of Perifosine Efficacy

Author

Hennessy, Bryan T., primary, Lu, Yiling, primary, Poradosu, Enrique, primary, Yu, Qianghua, primary, Yu, Shuangxing, primary, Hall, Hassan, primary, Carey, Mark S., primary, Ravoori, Murali, primary, Gonzalez-Angulo, Ana Maria, primary, Birch, Robert, primary, Henderson, I. Craig, primary, Kundra, Vikas, primary, and Mills, Gordon B., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table S1 from Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy

Author

Carey, Mark S., primary, Agarwal, Roshan, primary, Gilks, Blake, primary, Swenerton, Kenneth, primary, Kalloger, Steve, primary, Santos, Jennifer, primary, Ju, Zhenlin, primary, Lu, Yiling, primary, Zhang, Fan, primary, Coombes, Kevin R., primary, Miller, Dianne, primary, Huntsman, David, primary, Mills, Gordon B., primary, and Hennessy, Bryan T., primary

Published
2023
Full Text
View/download PDF

26. Data from Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy

Author

Carey, Mark S., primary, Agarwal, Roshan, primary, Gilks, Blake, primary, Swenerton, Kenneth, primary, Kalloger, Steve, primary, Santos, Jennifer, primary, Ju, Zhenlin, primary, Lu, Yiling, primary, Zhang, Fan, primary, Coombes, Kevin R., primary, Miller, Dianne, primary, Huntsman, David, primary, Mills, Gordon B., primary, and Hennessy, Bryan T., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data from c-Jun-NH2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer

Author

Vivas-Mejia, Pablo, primary, Benito, Juliana Maria, primary, Fernandez, Ariel, primary, Han, Hee-Dong, primary, Mangala, Lingegowda, primary, Rodriguez-Aguayo, Cristian, primary, Chavez-Reyes, Arturo, primary, Lin, Yvonne G., primary, Carey, Mark S., primary, Nick, Alpa M., primary, Stone, Rebecca L., primary, Kim, Hye Sun, primary, Claret, Francois-Xavier, primary, Bornmann, William, primary, Hennessy, Bryan T.J., primary, Sanguino, Angela, primary, Peng, Zhengong, primary, Sood, Anil K., primary, and Lopez-Berestein, Gabriel, primary

Published
2023
Full Text
View/download PDF

29. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Author

Oza, Amit M, Cook, Adrian D, Pfisterer, Jacobus, Embleton, Andrew, Ledermann, Jonathan A, Pujade-Lauraine, Eric, Kristensen, Gunnar, Carey, Mark S, Beale, Philip, Cervantes, Andrés, Park-Simon, Tjoung-Won, Rustin, Gordon, Joly, Florence, Mirza, Mansoor R, Plante, Marie, Quinn, Michael, Poveda, Andrés, Jayson, Gordon C, Stark, Dan, Swart, Ann Marie, Farrelly, Laura, Kaplan, Richard, Parmar, Mahesh K B, and Perren, Timothy J

Published
2015
Full Text
View/download PDF

31. Corrigendum to “Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes” [Gynecologic Oncology, Volume 157, Issue 1, April 2020, Pages 36–45]

Author

Scott, Stephanie A., primary, Fernandez, Marta Llaurado, additional, Kim, Hannah, additional, Elit, Laurie, additional, Nourmoussavi, Melica, additional, Glaze, Sarah, additional, Roberts, Lesley, additional, Offman, Saul L., additional, Rahimi, Kurosh, additional, Lytwyn, Alice, additional, Sur, Monalisa, additional, Gilks, C. Blake, additional, Matheson, Kara, additional, Köbel, Martin, additional, Dawson, Amy, additional, Tinker, Anna V., additional, Kwon, Janice S., additional, Hoskins, Paul, additional, Santos, Jennifer L., additional, Cheung, Andrea, additional, Provencher, Diane, additional, and Carey, Mark S., additional

Published
2022
Full Text
View/download PDF

32. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

Author

Llaurado Fernandez, Marta, primary, Hijmans, E. Marielle, additional, Gennissen, Annemiek M.C., additional, Wong, Nelson K.Y., additional, Li, Shang, additional, Wisman, G. Bea A., additional, Hamilton, Aleksandra, additional, Hoenisch, Joshua, additional, Dawson, Amy, additional, Lee, Cheng-Han, additional, Bittner, Madison, additional, Kim, Hannah, additional, DiMattia, Gabriel E., additional, Lok, Christianne A.R., additional, Lieftink, Cor, additional, Beijersbergen, Roderick L., additional, de Jong, Steven, additional, Carey, Mark S., additional, Bernards, René, additional, and Berns, Katrien, additional

Published
2022
Full Text
View/download PDF

35. Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response

Author

Stewart, Adam R., primary, Pickard, Lisa, additional, Paranjape, Ekta, additional, Perez, Victoria Sanchez, additional, Chowdhury, Sanjib, additional, Lustgarten, Stephanie, additional, Coma, Silvia, additional, Pachter, Jonathan A., additional, Carey, Mark S., additional, DiMattia, Gabriel, additional, Badham, Hannah C., additional, Prout, Toby, additional, Parmar, Mona, additional, Mahmud, Muneeb, additional, Yap, Christina, additional, Krebs, Matthew G., additional, Banerjee, Susana, additional, and Banerji, Udai, additional

Published
2022
Full Text
View/download PDF

36. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

Author

Stark, Dan, Nankivell, Matthew, Pujade-Lauraine, Eric, Kristensen, Gunnar, Elit, Lorraine, Stockler, Martin, Hilpert, Felix, Cervantes, Andrés, Brown, Julia, Lanceley, Anne, Velikova, Galina, Sabate, Eduardo, Pfisterer, Jacobus, Carey, Mark S, Beale, Philip, Qian, Wendi, Swart, Ann Marie, Oza, Amit, and Perren, Tim

Published
2013
Full Text
View/download PDF

40. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth

Author

Nieman, Kristin M., Kenny, Hilary A., Penicka, Carla V., Ladanyi, Andras, Buell-Gutbrod, Rebecca, Zillhardt, Marion R., Romero, Iris L., Carey, Mark S., Mills, Gordon B., Hotamisligil, Gokhan S., Yamada, S.Diane, Peter, Marcus E., Gwin, Katja, and Lengyel, Ernst

Subjects
Metastasis -- Development and progression -- Genetic aspects -- Research, Ovarian cancer -- Development and progression -- Genetic aspects -- Research, Fat cells -- Physiological aspects -- Genetic aspects, Biological sciences, Health
Abstract

Intra-abdominal tumors, such as ovarian cancer (1,2), have a clear predilection for metastasis to the omentum, an organ primarily composed of adipocytes. Currently, it is unclear why tumor cells preferentially home to and proliferate in the omentum, yet omental metastases typically represent the largest tumor in the abdominal cavities of women with ovarian cancer. We show here that primary human omental adipocytes promote homing, migration and invasion of ovarian cancer cells, and that adipokines including interleukin-8 (IL-8) mediate these activities. Adipocyte-ovarian cancer cell coculture led to the direct transfer of lipids from adipocytes to ovarian cancer cells and promoted in vitro and in vivo tumor growth. Furthermore, coculture induced lipolysis in adipocytes and β-oxidation in cancer cells, suggesting adipocytes act as an energy source for the cancer cells. A protein array identified upregulation of fatty acid-binding protein 4 (FABP4, also known as aP2) in omental metastases as compared to primary ovarian tumors, and FABP4 expression was detected in ovarian cancer cells at the adipocyte-tumor cell interface. FABP4 deficiency substantially impaired metastatic tumor growth in mice, indicating that FABP4 has a key role in ovarian cancer metastasis. These data indicate adipocytes provide fatty acids for rapid tumor growth, identifying lipid metabolism and transport as new targets for the treatment of cancers where adipocytes are a major component of the microenvironment., Most ovarian cancers are diagnosed at an advanced stage when the tumor is widely metastatic (1,2). The most common subtype is serous ovarian cancer, which may arise from the surface [...]

Published
2011
Full Text
View/download PDF

42. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability

Author

Shrestha, Raunak, primary, Llaurado Fernandez, Marta, additional, Dawson, Amy, additional, Hoenisch, Joshua, additional, Volik, Stanislav, additional, Lin, Yen-Yi, additional, Anderson, Shawn, additional, Kim, Hannah, additional, Haegert, Anne M., additional, Colborne, Shane, additional, Wong, Nelson K.Y., additional, McConeghy, Brian, additional, Bell, Robert H., additional, Brahmbhatt, Sonal, additional, Lee, Cheng-Han, additional, DiMattia, Gabriel E., additional, Le Bihan, Stephane, additional, Morin, Gregg B., additional, Collins, Colin C., additional, and Carey, Mark S., additional

Published
2021
Full Text
View/download PDF

45. Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities

Author

Cheasley, Dane, primary, Nigam, Abhimanyu, additional, Zethoven, Magnus, additional, Hunter, Sally, additional, Etemadmoghadam, Dariush, additional, Semple, Timothy, additional, Allan, Prue, additional, Carey, Mark S, additional, Fernandez, Marta L, additional, Dawson, Amy, additional, Köbel, Martin, additional, Huntsman, David G, additional, Le Page, Cécile, additional, Mes‐Masson, Anne‐Marie, additional, Provencher, Diane, additional, Hacker, Neville, additional, Gao, Yunkai, additional, Bowtell, David, additional, deFazio, Anna, additional, Gorringe, Kylie L, additional, and Campbell, Ian G, additional

Published
2020
Full Text
View/download PDF

48. A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Author

Perren, Timothy J., Swart, Ann Marie, Pfisterer, Jacobus, Ledermann, Jonathan A., Pujade-Lauraine, Eric, Kristensen, Gunnar, Carey, Mark S., Beale, Philip, Cervantes, Andrés, Kurzeder, Christian, du Bois, Andreas, Sehouli, Jalid, Kimmig, Rainer, Stähle, Anne, Collinson, Fiona, Essapen, Sharadah, Gourley, Charlie, Lortholary, Alain, Selle, Frédéric, Mirza, Mansoor R., Leminen, Arto, Plante, Marie, Stark, Dan, Qian, Wendi, Parmar, Mahesh K.B., and Oza, Amit M.

Published
2011

50. Abstract B23: CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines

Author

Hoenisch, Joshua, primary, Kim, Hannah, additional, Dawson, Amy, additional, Lam, Nicole, additional, Cheasley, Dane A., additional, Gorringe, Kylie, additional, Campbell, Ian, additional, Huntsman, David G., additional, DiMattia, Gabriel, additional, Kobel, Martin, additional, Fernandez, Marta Llaurado, additional, and Carey, Mark S., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results